Functional Role for GPR55 in the periaqueductal gray
GPR55 在导水管周围灰质中的功能作用
基本信息
- 批准号:8827313
- 负责人:
- 金额:$ 30.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-04-01 至 2019-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAnalgesicsAreaBone DevelopmentBrainCNR2 geneCalciumCannabinoidsCell modelDataElectrophysiology (science)Endoplasmic ReticulumGlutamatesGoalsHealthImageIn VitroIndividualInfusion proceduresInjection of therapeutic agentInositolInterneuronsKnockout MiceLateralMarijuanaMediatingMembraneMidbrain structureMitochondriaModelingMolecular ModelsMusNAADPNeuraxisNeuronsNociceptionOutputPainPain ThresholdPain managementPathologyPathway interactionsPhenotypePhysiologyPropertyRattusReactive Oxygen SpeciesRegulationRoleRyanodine ReceptorsSeriesSignal TransductionSiteSliceSynapsesSynaptic MembranesSynaptic TransmissionTailTestingTherapeuticTherapeutic InterventionTranslatingWaterdrug of abusegamma-Aminobutyric Acidgenetic manipulationin vivoinflammatory neuropathic paininflammatory paininterdisciplinary approachlysophosphatidylinositolmidbrain central gray substancemolecular modelingnociceptive responsenovelpainful neuropathypresynapticreceptorresearch studyresponse
项目摘要
DESCRIPTION (provided by applicant): GPR55 has recently been identified as a lysophosphatidylinositol (LPI)-sensitive receptor that may also mediate some off-target effects of cannabinoids. The broad central nervous system (CNS) distribution of GPR55 suggests its involvement in central physiology and pathology. Characterization of GPR55-/- (knock-out) mice reveals roles for the GPR55 receptor in inflammatory pain, neuropathic pain, and bone development while other studies indicate that GPR55 activation is pro-carcinogenic. Importantly, GPR55-/- mice show decreased inflammatory and neuropathic pain. Further, inhibition of LPI-induced activation of GPR55 may reduce neuropathic pain. The main goal of this application is to uncover the functional role of this new receptor, GPR55, in the periaqueductal gray (PAG), one of the most important regions involved in pain modulation and also a primary site of action of many analgesic compounds including cannabinoids. Our preliminary data revealed activation of GPR55 receptors in the PAG produces increases in intracellular calcium and cytoplasmic and mitochondrial reactive oxygen species in primary neurons and depolarization of PAG neurons in midbrain slice cultures. Furthermore, activation of GPR55 in PAG significantly reduced the pain threshold in rats. In other words, the activation of GPR55 in the PAG has a pro-nociceptive function. Thus, manipulating GPR55 signaling could be a new target for pain management. We propose to test a new hypothesis that the activation of GPR55 in the PAG has nociceptive response and antagonizing this receptor could have analgesic function. In the experiments under specific Aim 1, we will evaluate the GPR55-dependent Ca2+ response in PAG neurons. Studies under Aim 2 will use electrophysiology to characterize the membrane and synaptic activity responses of PAG neurons to GPR55 activation. In aim 3, we will determine the in vivo effect of GPR55 agonist(s)/antagonist(s) on PAG in several pain models. These studies will demonstrate the functional role of GPR55 in PAG, with the objective of identifying novel targets for effective therapeutic interventions. Specifically, we will determine whether the inhibition of GPR55 by antagonist(s) can be used as potential therapeutics for pain management.
描述(由申请人提供):GPR 55最近被鉴定为溶血磷脂酰肌醇(LPI)敏感性受体,其也可能介导大麻素的一些脱靶效应。GPR 55广泛的中枢神经系统(CNS)分布表明其参与中枢生理学和病理学。GPR 55-/-(敲除)小鼠的表征揭示了GPR 55受体在炎性疼痛、神经性疼痛和骨发育中的作用,而其他研究表明GPR 55活化是促癌的。重要的是,GPR 55-/-小鼠表现出减少的炎性和神经性疼痛。此外,抑制LPS诱导的GPR 55活化可减少神经性疼痛。该应用的主要目标是揭示这种新受体GPR 55在导水管周围灰质(PAG)中的功能作用,PAG是参与疼痛调节的最重要区域之一,也是许多镇痛化合物(包括大麻素)的主要作用部位。我们的初步数据显示,在PAG中的GPR 55受体的激活产生在原代神经元中的细胞内钙和细胞质和线粒体活性氧的增加,以及在中脑切片培养物中PAG神经元的去极化。此外,PAG中GPR 55的激活显著降低大鼠的痛阈。换句话说,PAG中GPR 55的激活具有促伤害感受功能。因此,操纵GPR 55信号可能是疼痛管理的新目标。我们提出了一个新的假设,即PAG中GPR 55的激活具有伤害性反应,拮抗该受体可能具有镇痛功能。在特定目标1下的实验中,我们将评估PAG神经元中的GPR 55依赖性Ca 2+反应。目标2下的研究将使用电生理学来表征PAG神经元对GPR 55激活的膜和突触活性反应。在目的3中,我们将确定GPR 55激动剂/拮抗剂在几种疼痛模型中对PAG的体内作用。 这些研究将证明GPR 55在PAG中的功能作用,目的是确定有效治疗干预的新靶点。具体而言,我们将确定拮抗剂对GPR 55的抑制是否可用作疼痛管理的潜在治疗剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARY E ABOOD其他文献
MARY E ABOOD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARY E ABOOD', 18)}}的其他基金
Functional Role for GPR55 in the periaqueductal gray
GPR55 在导水管周围灰质中的功能作用
- 批准号:
8695904 - 财政年份:2014
- 资助金额:
$ 30.73万 - 项目类别:
Optimization of High Selectivity Antagonist Hits for the GPR55 Receptor
GPR55 受体高选择性拮抗剂命中的优化
- 批准号:
8479451 - 财政年份:2012
- 资助金额:
$ 30.73万 - 项目类别:
Optimization of High Selectivity Antagonist Hits for the GPR55 Receptor
GPR55 受体高选择性拮抗剂命中的优化
- 批准号:
8400947 - 财政年份:2012
- 资助金额:
$ 30.73万 - 项目类别:
Pamoic acid analogues as potent GPR35 agoinsts inducing antinociception
双羟萘酸类似物作为有效的 GPR35 激动剂诱导抗伤害
- 批准号:
7782591 - 财政年份:2009
- 资助金额:
$ 30.73万 - 项目类别:
Molecular Characterization of GPR35 and GPR55, Putative Cannabinoid Receptors
GPR35 和 GPR55(假定的大麻素受体)的分子表征
- 批准号:
8065417 - 财政年份:2008
- 资助金额:
$ 30.73万 - 项目类别:
Molecular Characterization of GPR35 and GPR55, Putative Cannabinoid Receptors
GPR35 和 GPR55(假定的大麻素受体)的分子表征
- 批准号:
7646619 - 财政年份:2008
- 资助金额:
$ 30.73万 - 项目类别:
Molecular Characterization of GPR35 and GPR55, Putative Cannabinoid Receptors
GPR35 和 GPR55(假定的大麻素受体)的分子表征
- 批准号:
7446100 - 财政年份:2008
- 资助金额:
$ 30.73万 - 项目类别:
Molecular Characterization of GPR35 and GPR55, Putative Cannabinoid Receptors
GPR35 和 GPR55(假定的大麻素受体)的分子表征
- 批准号:
7864275 - 财政年份:2008
- 资助金额:
$ 30.73万 - 项目类别:
Molecular Characterization of GPR35 and GPR55, Putative Cannabinoid Receptors
GPR35 和 GPR55(假定的大麻素受体)的分子表征
- 批准号:
8661145 - 财政年份:2007
- 资助金额:
$ 30.73万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 30.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 30.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 30.73万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 30.73万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 30.73万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 30.73万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 30.73万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 30.73万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 30.73万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 30.73万 - 项目类别: